

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/081637 A1

(51) International Patent Classification:

C07D 471/18 (2006.01) C07D 471/04 (2006.01)
C07D 471/22 (2006.01) C07D 487/08 (2006.01)
C07D 498/22 (2006.01) C07D 513/04 (2006.01)
C07D 403/14 (2006.01) C07D 519/00 (2006.01)

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/079038

(22) International Filing Date:

31 October 2022 (31.10.2022)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/128110

02 November 2021 (02.11.2021) CN

63/417,219

18 October 2022 (18.10.2022) US

(71) Applicant: ENLIVEN THERAPEUTICS, INC.

[US/US]; 6200 Lookout Road, Floor 1, Boulder, Colorado 80301-3319 (US).

(72) Inventors: LYSSIKATOS, Joseph P.; c/o EnLiven Therapeutics, Inc., 6200 Lookout Road, Floor 1, Boulder, Colorado 80301-3319 (US). KINTZ, Samuel; c/o EnLiven Therapeutics, Inc., 6200 Lookout Road, Floor 1, Boulder, Colorado 80301-3319 (US). REN, Li; c/o EnLiven Therapeutics, Inc., 6200 Lookout Road, Floor 1, Boulder, Colorado 80301-3319 (US). SU, Qiang; c/o Pharmaron Beijing Co., Ltd., 6 Tai-He Road BDA, Beijing, Beijing 100176 (CN).

(74) Agent: CHOING, Stephanie et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2

(57) Abstract: The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.



WO 2023/081637 A1